Scientist II, Antibody Engineering at Manifold Bio

Boston, Massachusetts, United States

Apply Now

Not SpecifiedCompensation

Mid-level (3 to 4 years)Experience Level

Full TimeJob Type

UnknownVisa

BiotechnologyIndustries

Requirements

B.S. or M.S. in Biochemistry, Molecular Biology, Chemical Engineering, Virology, or a related field, with 2–5 years of relevant industry experience; experience in regulated GLP/GMP environments preferred
Hands-on experience producing AAV in HEK293 (triple transfection) and/or baculovirus-Sf9 systems from ≤ 1 L to ≥ 550 L scale
Proficiency with downstream purification techniques including affinity and ion-exchange chromatography, density gradient based purification methods, and tangential-flow filtration
Familiarity with closed-system or single-use bioreactors and process automation is a plus
Experience with viral-genome titer assays (qPCR, ddPCR) and capsid quantification (ELISA, A260/280)
Working knowledge of purity and impurity assays such as SEC-HPLC/UHPLC, Capillary Gel Electrophoresis (CGE), LC-MS, SDS-PAGE, and host-cell protein/DNA ELISAs
Ability to troubleshoot analytical methods and interpret data to drive process decisions
Meticulous attention to detail and commitment to high laboratory standards, including electronic lab-notebook documentation
Excellent organizational and communication skills with the ability to manage multiple projects in a fast-paced environment
Collaborative mindset and a passion for integrating experimental and computational approaches to solve complex problems
Prior experience leading or supporting ≥ 1 × 10¹⁵ vg-scale AAV campaigns for NHP studies (preferred)
Familiarity with design-of-experiments (DoE), process characterization, and technology transfer to CDMOs (preferred)
Exposure to GMP quality systems, including drafting SOPs, batch records, and deviation investigations (preferred)
Experience with other viral vectors (e.g., lentivirus, adenovirus) or lipid-nanoparticle formulation (preferred)

Responsibilities

Produce, purify, and qualify AAV vector lots from DNA to study-ready material
Maintain and troubleshoot cell-culture systems and bioreactors
Develop and execute QC assays; analyze and report data
Drive process-optimization experiments to improve yield and quality
Draft and maintain SOPs, batch records, and other quality documents
Provide regular updates to team members

Skills

AAV production

AAV purification

transient transfection

affinity chromatography

ion-exchange chromatography

tangential-flow filtration

qPCR

ddPCR

ELISA

HPLC

CGE

cell culture

bioreactors

Manifold Bio

Designs precision biologics using in vivo methods

About Manifold Bio

Manifold Bio specializes in creating precision biologics for the pharmaceutical industry, focusing on drug design and development. Their main product is an in vivo drug design platform, which allows for testing drugs within living organisms rather than in laboratory settings. This platform utilizes mCodes™ technology, a unique protein barcoding system that enables the simultaneous study of multiple proteins in one experiment, making it particularly effective for complex biologics. Unlike other companies, Manifold Bio's approach to drug design is distinct because it integrates in vivo testing with advanced protein multiplexing capabilities. The company's goal is to expand their platform and collaborate with other pharmaceutical companies to develop new therapeutics.

Boston, MassachusettsHeadquarters

2020Year Founded

$58.8MTotal Funding

SERIES_ACompany Stage

Biotechnology, HealthcareIndustries

11-50Employees

Risks

Increased competition from companies like Insamo and Infinimmune.

Rapid AI and ML advancements may outpace Manifold Bio's current technology.

Regulatory challenges in in vivo testing could delay product development timelines.

Differentiation

Manifold Bio uses proprietary mCodes™ technology for protein multiplexing in drug design.

Their in vivo drug design platform is the first of its kind globally.

The company specializes in precision biologics, focusing on complex biologics development.

Upsides

Raised $40M in Series A funding, indicating strong market interest.

Their platform could revolutionize in vivo testing by testing multiple molecules simultaneously.

Strategic partnerships with multiple investors enhance growth and development opportunities.

Land your dream remote job 3x faster with AI

Try Jobo Free